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Abstract
Background: Depression is common in patients with coronary artery disease (CAD) and is associated with poorer
outcomes and higher costs. Several randomised controlled trials (RCTs) targeting depression, of various modalities
(including pharmacological, psychotherapeutic and other approaches), have been conducted and summarised in
pairwise meta-analytic reviews. However, no study has considered the cumulative evidence within a network, which
can provide valuable indirect comparisons and information about the relative efficacy of interventions. Therefore,
we will adopt a review of review methodology to develop a network meta-analysis (NMA) of depression
interventions for depression in CAD.
Methods: We will search relevant databases from inception for systematic reviews of RCTs of depression treatments
for people with CAD, supplementing this with comprehensive searches for recent or ongoing studies. We will
extract data from and summarise characteristics of individual RCTs, including participants, study characteristics,
outcome measures and adverse events. Cochrane risk of bias ratings will also be extracted or if not present will be
conducted by the authors.
RCTs that compare depression treatments (grouped as pharmacological, psychotherapeutic, combined pharmacological/
psychotherapeutic, exercise, collaborative care) to placebo, usual care, waitlist control or attention controls, or directly in
head-to-head comparisons, will be included. Primary outcomes will be the change in depressive symptoms (summarised
with a standardised mean difference) and treatment acceptability (treatment discontinuation: % of people who
withdrew). Secondary outcomes will include change in 6-month depression outcomes, health-related quality of
life (HRQoL), mortality, cardiovascular morbidity, health services use and adverse events. Secondary analyses will
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form further networks with individual anti-depressants and psychotherapies.
We will use frequentist, random effects multivariate network meta-analysis to synthesise the evidence for depression
intervention and to achieve a ranking of treatments, using Stata. Rankograms and surface under the cumulative
ranking curves will be used for treatment ranking. Local and global methods will evaluate consistency. GRADE will be
used to assess evidence quality for primary outcomes.
Discussion: The present review will address uncertainties about the evidence in terms of depression management in
CAD and may allow for a ranking of treatments, including providing important information for future research efforts.
Systematic review registration: PROSPERO CRD42018108293
Keywords: Depression, Coronary artery disease, Network meta-analysis, Systematic review, Randomised controlled trial,
Intervention,
Background
Depression is common in patients with coronary artery
disease (CAD) and negatively impacts on clinically im-
portant outcomes. For example, the prevalence of major
depression post-myocardial infarction reported to be
12–20%, with up to 38% reporting elevated depressive
symptoms [1, 2], which is higher than seen in commu-
nity samples [3]. Both major depression and depressive
symptoms have been associated with increased mortality,
morbidity, poorer quality of life, higher health service
utilisation and increased healthcare costs [1, 4, 5]. De-
pression in CAD is therefore an important treatment
target, and treatment interventions should be thoroughly
evaluated.
While a substantial body of research exists in terms of
depression interventions in those with CAD [4, 6–11],
the effects of both pharmacological and psychological
interventions are typically small [6, 8, 12]. Indeed, the ef-
fect sizes from these studies may even be smaller than
those seen in general population samples [13] or other
chronic conditions such as diabetes [14]. While exercise
interventions for depression in general populations are
effective [15] and show significant promise for depres-
sion in CAD [16, 17], exercise is often provided as part
of multi-component cardiac rehabilitation programmes
[10], which also contain some form of psychological
intervention and risk factor education. Yet participants
enrolled in such programmes are rarely enrolled primar-
ily for depression treatment [10]. Furthermore, depres-
sion is a known impediment to joining, and dropping
out, of such programmes [18, 19], meaning that com-
parison among such studies is unlikely to be appropriate
or informative. It is therefore difficult to determine the
efficacy of exercise alone. Furthermore, the contents of
psychological interventions—which often are described
as having a stress management component—are not al-
ways clear and can be highly variable [6, 9, 10, 12]. It is
therefore difficult to compare the effects of these inter-
ventions and make recommendations regarding the best
treatment choices for depression in the CAD population.
While ideally, direct comparisons of depression treat-
ments for CAD would provide clinicians and policy-makers
with excellent evidence for efficacy and acceptability of de-
pression interventions, currently, this data is not available.
However, there may be sufficient evidence of such interven-
tions to provide indirect comparisons [20]. Network
meta-analysis (NMA) is an advanced technique in that it
allows both direct comparisons (as does pairwise
meta-analysis), but also indirect comparisons for treatments
that have not been made in a head-to-head format, and is
recommended when competing interventions are used
[20–25]. It can therefore provide crucial evidence for clini-
cians that can account for multiple outcomes simultan-
eously and even provide a ranking of treatments (e.g.
treatment efficacy and acceptability to patients). Recent ex-
amples include (both direct and indirect) comparisons of
behavioural and pharmacological treatments for smoking
cessation [26] and comparison of second-generation
anti-depressants [13], among others.
Given the plethora of reviews and pairwise meta-analyses
in the field of CAD and depression (e.g. [4, 6–11, 25, 27],
yet the significant uncertainty that still remains in terms of
comparing treatments, it appears that NMA may provide
an important opportunity to summarise the current de-
pression intervention literature for those with CAD, in
terms of both efficacy and acceptability (the latter outcome
being largely neglected in pairwise meta-analyses). Indeed,
it has been noted that in the absence of several direct
head-to-head RCTs of competing interventions, or when
using more than one outcome to rank treatments, NMA is
the best available approach [20, 28]. A recent NMA of
second-generation anti-depressants excluded trials of pa-
tients with serious concomitant medical illness [13], such
as CAD, leaving a significant gap in the psychosomatic
literature.
However, performing NMA of psychological interven-
tions, where the content of interventions is unclear, is not
necessarily methodologically sound (or indeed for pairwise
meta-analysis)—we therefore will not address such inter-
ventions. However, established psychotherapies for
Doyle et al. Systematic Reviews            (2019) 8:71 Page 2 of 10
depression, which follow a theoretical framework and
standard procedures and are delivered by a trained psy-
chotherapist (which are often manualised, allowing for
replication), should be more comparable and are fre-
quently meta-analysed and indeed included in NMA [29–
31]. Furthermore, collaborative care, a multi-professional,
structured approach to depression management and en-
hanced communication and follow-up [11], can encom-
pass both combined psychotherapy and anti-depressant
usage. Such treatments—anti-depressants, psychother-
apies and collaborative care—have all been investigated in
recent RCTs in patients with CAD, have been combined
in other pairwise and network meta-analyses [11, 31, 32],
and should therefore be comparable for NMA. While ex-
ercise is an established treatment for depression [15], as
outlined above, it is usually encompassed in (heteroge-
neous) cardiac rehabilitation programmes, but where it
studied alone it could be compared to other interventions.
Objectives
The main objective of this NMA is to compare the best
established treatment(s) for depression in patients with
CAD in terms of efficacy (or effectiveness, in studies
using non-placebo comparators) and acceptability, with
several secondary outcomes also considered. Cardiac re-
habilitation will not be included, as this is currently
undergoing investigation elsewhere [33], but more im-
portantly because cardiac rehabilitation per se would not
be considered a front-line depression intervention. The
PICO is as follows:
– Participants: patients with CAD and elevated
depressive symptoms (clinical diagnosis of
depression [any clinical diagnosis of depression that
is made by a clinician or by structured diagnostic
interview], or scoring above threshold on any
validated depression scale) enrolled in randomised
trials for depression treatment in any setting,
excluding cardiac rehabilitation
– Interventions: any established treatment (groupings)
for depression, including pharmacotherapy,
psychotherapy, exercise and collaborative care
– Comparison: placebo groups, usual care or waitlist
control, attention control groups
– Outcomes:
o Primary: change in depressive symptoms at 8-
weeks;, acceptability (% of patients who discon-
tinue treatment),
o Secondary: change in depressive symptoms at 26
weeks, depression response (≥ 50% change in total
score on observer or self-report rating depression
scale [13]), health-related quality of life (HRQoL),
mortality (all-cause, cause specific), re-infarction
and other cardiac complications, health services
use, adverse events
Methods and analysis
We use the PRISMA-P and PRISMA extension state-
ment for NMA guidelines for reporting this protocol
[28, 34, 35] (see Additional file 1). This protocol has
been registered on PROSPERO (CRD42018108293).
Criteria for considering studies for this review: eligibility
criteria
Study types
We will include all randomised trials of interventions for
depression in patients with CAD, including pharmaco-
therapy, psychotherapy, exercise or collaborative care,
which use a validated depression scale or diagnostic inter-
views as an outcome measure, and report a (potential)
change in depressive symptoms from baseline or
pre-treatment to post-treatment. Cross-over or cluster
RCTs will be included, but quasi-RCTs or those focusing
on cardiac rehabilitation, or psychological interventions
that are not established psychotherapies delivered by
trained therapists, will be excluded. Studies will be pub-
lished or summarised in peer-reviewed journals or review
articles, or RCT registries, in the English language. If rele-
vant RCTs are not summarised sufficiently in English in
any found review, we will exclude them. Although this
may lead to publication bias, exclusion of non-English ar-
ticles is typical in this field [4, 11, 12, 27].
Participants
Participants will be aged 18 years and over, diagnosed with
CAD (including acute coronary syndrome, angina, angio-
graphically confirmed coronary disease, receipt of percutan-
eous coronary intervention or coronary bypass graft), and
be enrolled in an RCT that targets elevated depression
(clinical diagnosis of depression or scoring above threshold
on a validated scale) as either a primary or secondary out-
come, with a validated depression scale score at baseline or
pre-enrolment, and post-intervention, from which to calcu-
late change scores. If RCTs have combined CAD and other
patients with coronary heart disease diagnoses, authors will
be requested to provide estimates for CAD patients only.
Otherwise, if ≥ 70% of participants have a diagnosis of
CAD, the overall trial estimates will be included. We will
exclude studies where ≥ 20% of people have bipolar or
psychotic depression, or where all participants have concur-
rent secondary psychiatric diagnoses [36].
Intervention types
We will include the following groups of interventions:
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– Pharmacotherapies: selective serotonin re-uptake in-
hibitors, monoamine oxidase inhibitors, tricyclic
anti-depressants, anxiolytics etc.
– Psychotherapy trials delivered by trained therapists:
cognitive-behavioural therapy, interpersonal psycho-
therapy, mindfulness, acceptance and commitment
therapy, behavioural therapy, cognitive remediation,
cognitive stimulation therapy, dialectical behaviour
therapy, family systems therapy, integrative psycho-
therapy, multimodal therapy, positive psychology in-
terventions, problem-solving therapy,
psychodynamic psychotherapy, supportive therapy
and counselling.
– Combination therapies (pharmacotherapies with
psychotherapy): a combination of the above two
interventions
– Exercise: specific exercise targeting depression, but
not (multi-component) cardiac rehabilitation.
– Collaborative care: interventions that are labelled by
trial authors specifically as collaborative care
programmes and meet accepted criteria [11, 37,
38](depression care interventions including all of the
following: a multi-professional approach, structured
management plan, scheduled follow-up, enhanced
inter-professional communication).
Given the previous evidence supporting these depres-
sion interventions in CAD, we assume that included pa-
tients are equally likely to have been randomised to any
of the interventions described above [28]. As recom-
mended, unspecified interventions (e.g. complementary
and alternative therapies) may be included, post hoc, in
the network, if they are deemed to supply vital informa-
tion for increasing precision of the results [28], but
otherwise will not be included. Such additions will be
carefully documented and reported.
Comparison groups
RCTs which compare to pill placebo control groups, or
other comparator groups [39], or directly in a
head-to-head format, will be included. Non-placebo con-
trol groups can differ substantially from various forms of
control designs in psychotherapeutic research, with con-
siderable implications for study effect sizes and conduct-
ing of NMA [39, 40]. Previous research has shown that
other comparator groups can include no treatment, treat-
ment as usual, waitlist control (experimental treatment is
offered after post-treatment assessment), minimal treat-
ment control (fewer than four treatments), active com-
parator (evidence-based treatment), non-specific factor
component control (equivalent time with interventionist
but without specific therapeutic content), specific factor
component control (equivalent time with interventionist
with different or reduced therapeutic content), no
treatment control, patient’s choice (personal preference
for offered treatments) [39, 40]. However, there is likely to
be far more limited literature in the current area of de-
pression in CAD. Therefore, following a recommended
framework [40], these comparator groups will be com-
bined to allow for more appropriate comparison, as fol-
lows: (1) pill placebo; (2) no treatment, waitlist or
treatment as usual; and (3) minimal treatment control, ac-
tive comparator, specific and non-specific factors treat-
ment control. Where the classification of comparison
groups is unclear, authors will be contacted to request fur-
ther detail. If this is not forthcoming, we will use another
grouping of ‘unclear’ or eliminate the study from the
NMA. The currently proposed network plot of all possible
comparisons is shown in Fig. 1.
Outcomes
Primary outcomes
We will adopt two primary outcomes, similar to those of
a recent NMA of anti-depressant therapy and other re-
views in similar areas [6, 11, 13], as follows:
1. Efficacy (effectiveness)-response (continuous):
change in depressive symptoms (as measured by
validated tools and summarised with standardised
mean difference [SMD]) at week 8 post-
intervention (or closest measure to 8 weeks that is
available, between 4 and 16 weeks)
2. Acceptability: defined as the proportion of
participants who discontinue treatment (for any
reason [such reasons will be recorded where
available]) between 4 and 16 weeks after initial
intervention.
Secondary outcomes
1. Efficacy (effectiveness)-response (continuous):
change in depressive symptoms (as measured by
validated tools and summarised with standardised
mean difference (SMD)) at week 26 post-
intervention (or closest measure to 26 weeks that is
available, between 20 and 30 weeks)
2. HRQoL: change in HRQoL scores summarised
using SMD. If HRQoL scores are not available, then
generic QoL scores will be used as appropriate.
3. Mortality: the proportion of participants who die
during or after treatment, for the longest duration
of available data. All-cause mortality will be pre-
ferred, but substituted with cardiovascular mortality
if unavailable. If sufficient data is available, both all-
cause and cause-specific mortality will be modelled
separately.
4. Morbidity: the proportion of participants who have
re-infarction or recurrent PCI or CABG, or other
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acute coronary events/interventions, during or after
treatment, for the longest duration of available data.
5. Health services use: the proportion of participants
who have hospital re-admission and/or primary care
practitioner visits, for the longest duration of avail-
able data.
6. Adverse events: the proportion of participants who
leave the study due to adverse events within 8
weeks of study commencement (range 4–16 weeks)
Search strategy and study selection
As several systematic reviews have already been pub-
lished in this area (e.g. [6–11]), we will conduct a hybrid
overview of reviews [31] and systematic review method-
ology. We will find and extract RCTs and their associ-
ated data using the content of these reviews and the
original RCT papers (including RCTs which are listed as
not having being included in the final published reviews
(e.g. [6, 9]). This will be supplemented by an updated
search for RCTs, as is commonly done in other areas
[41–43]. More precisely, we will search, from inception,
the Cochrane Library (CENTRAL), CINAHL, MED-
LINE/PubMed, EMBASE, MEDLINE In-Process, Episte-
monikos and PsycInfo. Then, we will conduct a search
of MEDLINE/PubMed and the Cochrane Library for re-
cent RCTs published in the last 5 years (i.e. from 1st
January 2014). We will also supplement this with a
search of clinical trials registries: World Health
Organization International Clinical Trials Registry Plat-
form (WHO ICTRP) and clinicaltrials.gov, using similar
terms. The reference lists for included RCTs will also be
searched. Unpublished data will be requested for unpub-
lished or ongoing studies, but data from abstracts only
will be excluded. Searches will not be filtered by lan-
guage, but non-English language articles will be omitted
at the title screening stage. All search terms are provided
in Additional file 2.
All references will be downloaded into EndNote or
Reference Manager, and duplicates will be found and
removed using the software automatic tools. Reviews
and trials will be selected by FD and MD independently,
with discussion as needed. If both reviewers agree that
an RCT does not meet the inclusion criteria, it will be
excluded from further analysis. Then, full texts of all eli-
gible RCTs will be obtained and reviewed for final inclu-
sion. Disagreements will be discussed with a third
reviewer.
Data extraction
RCT data will be extracted independently by FD and MD.
We will adopt a structured data extraction form designed
for the present review, to enhance the completeness and
consistency of data extraction. Data extracted will include
study characteristics (first author, year of publication, jour-
nal, setting), participant characteristics (sample size, mean
age, % women, inclusion criteria [for CAD and depres-
sion], intervention details (anti-depressant [dose, duration,
dosing schedule]; for psychotherapy interventions the
TIDiER checklist headings will be adopted for extraction
criteria (i.e. brief name of intervention, rationale/theory,
Fig. 1 Network of possible comparisons between intervention and comparator groupings
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materials, procedures, who provided the intervention,
mode of delivery, location/setting, dose/intensity, tailoring,
modifications, fidelity) [44]. While obviously the content
of psychotherapies can be heterogeneous, the use of
TIDiER headings will allow the careful documentation of
any significant disparities in content and delivery forms
that may necessitate subsequent sensitivity analysis, al-
though it is difficult to estimate this a priori. TIDiER will
also be used to fully describe the comparison groups, prior
to grouping for the NMA analysis (see above). Outcomes
data will also be extracted—see below for details. Sum-
mary effect sizes will be calculated from data extracted
from the RCTs, including multi-arm (three or more
groups) trials, where data will be extracted at the arm level
from the original reports. Two review authors will verify
that the data has been inputted correctly into the final
dataset.
Continuous outcomes
SMDs and 95% confidence intervals, or means, SDs
and number of patients in each trial arm will be ex-
tracted for continuous outcomes. Otherwise, the au-
thors will be emailed to request the data. If some
data is omitted (e.g. missing SDs or if p values only
are reported), we will use the metaeff command pro-
cedures in Stata to calculate SMDs and 95% confi-
dence intervals from available data [45]. If insufficient
data is available to calculate the SMD, we will include
the study for descriptive purposes only and omit the
study from the main network analyses. If insufficient
data is available to calculate the 95% confidence inter-
vals, we will impute this will the median from the
other studies within that particular grouping. If > 5%
of studies require such imputation, we will consider
multiple imputation techniques. A sensitivity analysis
will be conducted to determine if there are any im-
portant implications of such imputation.
Binary outcomes
The numbers of participants in each arm with each
event will be extracted for each trial arm. If data is un-
available, we will contact the authors. Values will be im-
puted where continuous data is provided instead of
numeric values, using an approved method [46].
Duration of RCTs and outcome assessments
For the synthesis of primary outcomes and the second-
ary outcomes of adverse events, we will adopt the
8-week threshold as per the previous review, or, if data
is unavailable for this duration, we will use the closest
available data from 4 to 16 weeks [13, 36]. If data on ad-
verse events (dropout) is not available for this time
period, we will consider using the overall dropout rate as
a proxy. This was adopted as researchers believed that
depression treatments should work in a clinically reason-
able period of time. We will adopt a longer-term,
6-month depression assessment as a secondary outcome.
For other outcomes, data from the longest duration of
follow-up will be obtained.
Missing RCT outcome data
We will primarily adopt the results as reported in the
original trials, irrespective of whether they adopted ap-
propriate methods for dealing with missing data or not
(e.g. reporting per protocol results instead of
intention-to-treat). Ratings of the appropriateness or
otherwise of the missing data imputation is already part
of the risk of bias assessment conducted in prior
meta-analyses (e.g. [6, 11]).
Unit of analysis
We will adopt the methods of the recent anti-depressant
NMA when dealing with a unit of analysis issues [13, 36],
if these were not addressed by the obtained meta-analyses.
Data extracted for cluster RCTs will account for clustering
in the design (e.g. we will use data from multi-level
models), whereas data from only the first period of
cross-over trials will be used, due to potential carryover
effects.
Risk of bias and quality ratings
Where available, we will extract the Cochrane risk of bias
tool [47] ratings from prior reviews (e.g. [6, 11]). Where
published reviews disagree on the quality rating, or where
there is no such rating, FD and MD will independently as-
sess included RCTs using this Cochrane risk of bias tool,
with disagreements discussed and resolved with a third
team member. Risk of bias will be assessed for the following
design areas (for placebo-controlled trials): generation of
allocation sequence, allocation concealment, blinding of
outcome assessor, attrition (adopting similar criteria to Fur-
ukawa et al. [13, 36]), selective outcome reporting (for the
primary outcomes only) and other domains (e.g. sponsor-
ship bias). If any details are inadequate, RCT authors will be
contacted for missing information. Given the nature of
complex or psychotherapeutic interventions, assessing the
blinding of treatment assignment is not usually possible, so
it is likely that most of these trials will exhibit high risk of
bias, whereas the placebo-controlled drug trials will be less
biassed. We will also consider whether different risks of
bias estimates are needed for particular arms of multi-arm
trials [28]. When comparing the trials, the blinding of out-
come assessments will take precedence [9].
We will also follow the recommendations for NMA
and use the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) framework for
obtained results [13, 36, 48]. This framework charac-
terises the overall evidence contributing to the main
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outcomes from the network estimates incorporating in-
formation from the study limitations, imprecision, in-
consistency, indirectness and publication bias, any of
which could downgrade the obtained summary evidence
[49]. GRADE ratings will be presented in a summary
findings table.
Statistical analysis
Descriptive statistics for the RCTs will be used to profile
the overall study and clinical features, such as publica-
tion year, age, proportions of women, clinical setting,
number of trial arms, intervention content and com-
parator group content. A network diagram will be used,
with node size indicating the number of patients for
each treatment (or comparator) group, and edge width
used as an indicator of the numbers of studies making
the comparison [20]. Several comparator groups will be
used in the main network, as outlined in the ‘Compari-
son groups’ section above. The most influential network
comparisons will be evaluated using a contribution
matrix, which describes the proportion of the contribu-
tion to the entire network of each direct meta-analysis
[50]. Two main networks will be evaluated using fre-
quentist multivariate meta-analysis (commands network
meta and mvmeta, which underpins the first command)
in Stata 15 [51]. These commands perform restricted
maximum likelihood methods for random effects multi-
variate meta-analysis by using a Newton-Raphson pro-
cedure, accounting for within- and between-study
correlations. The assumptions of this model are that the
multiple modelled effects represent a multivariate nor-
mal approximation of the estimated effects; that a multi-
variate linear regression can be performed due to linear
effects between studies; a constant between-studies co-
variance matrix, where conditional variances of all com-
ponents of the random effect are constant; and a
symmetrical normal distribution which does not allow
for light or heavy tails (which consequently means that
outlier trial results can be overly influential for final esti-
mates) [51]. The interested reader is referred to the fol-
lowing references for more detail [51, 52].
The first analysis will contain the original groupings as
outlined above (i.e. pharmacotherapy, psychotherapies,
exercise, collaborative care, comparator groups). A sec-
ond main analysis will separate the different groupings,
i.e. by type of anti-depressant (e.g. fluoxetine, sertraline),
type of psychotherapy (e.g. CBT, interpersonal psycho-
therapy, mindfulness), if there is enough available data.
Any derived ranking of treatments will only be done for
primary outcomes, although given the probable sparsity
of evidence we acknowledge in advance that this ranking
may have a substantial error. As some trials may not re-
port change scores, but may report end-of-trial scores
only, we will consider a supplementary analysis where
we include the end-of-trial only scores if this is required
to generate the network, or there is likely to be substan-
tial missing data (i.e. > 10% of trial estimates missing).
As interventions are by definition heterogeneous, ran-
dom effects pairwise meta-analyses will be used to ob-
tain SMDs or odds ratios (with associated 95%
confidence intervals) for continuous and binary out-
comes respectively [51, 53], with the I2 statistic used to
quantify heterogeneity. All pairwise estimates and associ-
ated 95% confidence intervals will be reported. Pairwise
meta-analytic estimates are usually reported in addition
to the network estimates [13, 36, 52]. Among other rea-
sons, they are useful (1) to determine the potential ef-
fects of any outliers and (2) to demonstrate any
differences in estimated effects from the network
meta-analysis which could be attributed to the correl-
ation between the outcomes—which is ignored in a pair-
wise meta-analysis [52].
Transitivity is a key assumption of NMA and refers to
the belief that an indirect comparison is a valid estimate of
the unobserved direct comparison [48]. The transitivity
assumption was initially addressed by the inclusion of pa-
tients with CAD only—as treatments for CAD are largely
similar, i.e. risk factor control such as hypertension man-
agement, lipid-lowering and smoking cessation—these
patients were considered similar enough for synthesising
the information. Transitivity assessment will follow previ-
ous research [13, 36, 48]—by investigating effect modifiers
across treatment comparisons, such as subthreshold de-
pression or baseline depression severity, age, dosing (or in-
tensity) [54–56], sex and cardiovascular disease severity
[2], and differences in placebo-controlled versus other
comparator group studies [39, 40]. Comparing the relative
distribution of such variables across RCTs may provide
some evidence for this assumption. Furthermore, we will
compare the placebo-controlled trials to any head-to-head
trials to ascertain any differences [36]. We assume that all
RCT participants would have had equal opportunity to be
randomised to any of the trial arms (apart from any poten-
tial patient preference studies). If transitivity is not dem-
onstrated (e.g. if there are clear, statistically significant
and/or clinically important differences in patients enrolled
to trials in terms of age, sex, CAD or depression severity
indices [48]), we may explore building separate networks
to reflect the evidence.
Prior to conducting the NMA, inconsistency, which is
the disagreement between direct and indirect evidence
[48], will be assessed using both local and global methods
in Stata as appropriate, and also by calculating the I2 for
network heterogeneity and inconsistency [20, 28, 50, 57].
Heterogeneity variance will be considered equal within
groupings, but possibly different among groups. Local
parts of the network will be evaluated using the
loop-specific and node-splitting methods. The global
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network will be evaluated using a design-by-treatment
interaction model. We will also display inconsistency fac-
tors as recommended, but will use caution in interpret-
ation due to the chance of finding inconsistency by
chance alone, or have wide 95% confidence intervals [20].
Sensitivity analysis will also mainly follow previous
work [13, 36]—the treatment effects for the primary out-
comes will be explored in subgroup analysis and
meta-regression for the following variables: study year,
RCT sponsorship/funding (industry versus government/
charity), baseline depression severity, intervention inten-
sity or dosing schedule, comparator grouping, study de-
sign, setting or country. Where practicable, analyses will
also be conducted addressing enrolment period: studies
that enrol patients up to 6 months after an acute coron-
ary event (or those that assess depressive symptoms on
two or more occasions prior to enrolment) versus those
that enrol stable patients or 6 months after an acute
event; studies that provide depression treatment choice
versus those that do not. Sensitivity analysis will address
different levels of risk of bias (low, medium, high) [58],
but also intensity of interventions as rated by a dichot-
omous variable (as rated by FD and MD, i.e. using the
recommended to maximum doses of pharmacotherapies
or greater than four sessions of psychotherapies—these
will be classified as high-intensity interventions; other-
wise, low dosage pharmacotherapy or four or fewer ses-
sions of psychotherapy will be classed as low-intensity).
Funnel plots for NMA, which plot the difference be-
tween the study-specific effect sizes from the corre-
sponding comparison-specific summary versus the
inverted standard error, will be used to ascertain whether
estimates from more imprecise RCTs are different from
those RCTs with more precision (such as larger effect
sizes for depression treatment in smaller studies) [28,
50]. A network meta-regression will investigate associa-
tions between effect size and study sample size.
Rankograms and surface under the cumulative ranking
(SUCRA) curves will be used for treatment ranking [20].
SUCRA can be usefully re-expressed as the percentage
of effectiveness/acceptability of depression interventions
that would be rated first ranking, without uncertainty.
Although we will report the probability that a given
treatment is best, second best, third best etc., such prob-
ability statements will be interpreted cautiously unless
there are actual clinically meaningful differences among
the interventions.
All analyses will be implemented in Stata 15.
Discussion
This will be the first NMA to provide a ranking of treat-
ments for depression in those with CAD and should
provide insights into the future development and imple-
mentation of the most promising effective methods. The
adopted methodology, combining overview and compre-
hensive systematic review techniques for newer litera-
ture, as is common [41–43], should reduce duplication
of effort yet provide a relatively quick and comprehen-
sive answer to support clinical decision-making.
The results could show treating doctors whether it is
better to initiate anti-depressant treatment, or refer for
psychotherapy or other treatments, or both. Results
should provide researchers with vital insights into effect-
ive interventions and funders with valuable information
on the allocation of future research resources.
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